Quick Answer
Larimar Therapeutics, Inc. reported Diluted EPS of $1.32 per share (loss) for fiscal year 2024.
Larimar Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2024 | -$1.32 | -57.1% |
| 2023 | -$0.84 | +38.7% |
| 2022 | -$1.37 | +53.6% |
| 2021 | -$2.95 | +17.4% |
| 2020 | -$3.57 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.61 | -154.2% | -48.8% |
| June 30, 2025 | -$0.41 | -20.6% | +10.9% |
| March 31, 2025 | -$0.46 | -70.4% | -91.7% |
| September 30, 2024 | -$0.24 | -14.3% | +29.4% |
| June 30, 2024 | -$0.34 | -78.9% | -25.9% |
| March 31, 2024 | -$0.27 | -80.0% | -28.6% |
| September 30, 2023 | -$0.21 | +43.2% | -10.5% |
| June 30, 2023 | -$0.19 | +59.6% | -26.7% |
- Larimar Therapeutics, Inc. showed a decrease of -57.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2024 period, Larimar Therapeutics, Inc.’s diluted eps has grown by 63.0% (from $3.57 per share (loss) to $1.32 per share (loss)).
- The most recent figure is from Larimar Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: